OTCMKTS:ARTHArch Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arch Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.20 -0.02 (-8.49 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.20Now: $0.20▼$0.2250-Day Range$0.18MA: $0.20▼$0.2352-Week Range$0.12Now: $0.20▼$0.38Volume410,565 shsAverage Volume274,567 shsMarket Capitalization$37.29 millionP/E RatioN/ADividend YieldN/ABeta0.2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArch Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.63, Arch Therapeutics has a potential upside of 714.5% from its current price of $0.20.Amount of Analyst CoverageArch Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesArch Therapeutics has received 192 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArch Therapeutics has received 216 “underperform” votes. (Add your “underperform” vote.)Community SentimentArch Therapeutics has received 52.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote “Outperform” if you believe ARTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArch Therapeutics does not currently pay a dividend.Dividend GrowthArch Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arch Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.01% of the stock of Arch Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arch Therapeutics are expected to remain at ($0.03) per share in the coming year. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone617-431-2313Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio2.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,550,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-137.14%Miscellaneous Employees8 Outstanding Shares186,900,000Market Cap$37.29 million Next Earnings Date8/6/2020 (Estimated) OptionableNot Optionable OTC:ARTH Rates by TradingView Receive ARTH News and Ratings via Email Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter. Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions How has Arch Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Arch Therapeutics' stock was trading at $0.2050 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARTH shares have decreased by 2.7% and is now trading at $0.1995. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arch Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arch Therapeutics. When is Arch Therapeutics' next earnings date? Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Arch Therapeutics. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics Inc (OTCMKTS:ARTH) posted its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). View Arch Therapeutics' earnings history. What price target have analysts set for ARTH? 2 analysts have issued 1 year price targets for Arch Therapeutics' stock. Their forecasts range from $1.25 to $2.00. On average, they expect Arch Therapeutics' share price to reach $1.63 in the next year. This suggests a possible upside of 714.5% from the stock's current price. View analysts' price targets for Arch Therapeutics. Has Arch Therapeutics been receiving favorable news coverage? Media stories about ARTH stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arch Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutArch Therapeutics. Who are some of Arch Therapeutics' key competitors? Some companies that are related to Arch Therapeutics include Apyx Medical (APYX), T2 Biosystems (TTOO), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), PAVmed (PAVM), Spectral Medical (EDTXF), Venus Concept (VERO), SANUWAVE Health (SNWV), BRAINSWAY LTD/S (BWAY), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS) and STRATA Skin Sciences (SSKN). View all competitors. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), POET Technologies (POETF), Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Bellerophon Therapeutics (BLPH), Actinium Pharmaceuticals (ATNM), Antares Pharma (ATRS), Reshape Lifesciences (RSLS) and Biocept (BIOC). Who are Arch Therapeutics' key executives? Arch Therapeutics' management team includes the following people: Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)Mr. Richard E. Davis, CFO & Treasurer (Age 61)Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific AdvisorDr. Steven A. Kates Ph.D., VP of Technology What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How do I buy shares of Arch Therapeutics? Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $0.20. How big of a company is Arch Therapeutics? Arch Therapeutics has a market capitalization of $37.29 million. Arch Therapeutics employs 8 workers across the globe. What is Arch Therapeutics' official website? The official website for Arch Therapeutics is www.archtherapeutics.com. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
